Navigation Links
Overabundance of Immune Cells Might Trigger Lupus
Date:2/14/2008

Study spots overactivity of genes that prevent cell death in those with autoimmune disease

THURSDAY, Feb. 14 (HealthDay News) -- Researchers from Saint Louis University report that a pile-up of superfluous immune cells might contribute to lupus, a finding which could point to new therapies for the autoimmune disease.

"We're on the precipice of finding new treatments for lupus," said Dr. Jill Buyon, a professor of medicine at New York University School of Medicine. "There are a myriad of targets at different levels of the immune system. What we're seeking are therapies that are targeted that would not cause patients to have overwhelming infection [as side effects]. This paper supports the notion that such therapeutic approaches might be possible."

More than 1.5 million Americans have lupus, a disease in which a hyperactive immune system assaults otherwise healthy organs, such as the kidney, brain, heart, lungs and skin, as well as joints and blood.

The current standard of treatment typically involves nonsteroidal anti-inflammatory drugs (NSAIDs), anti-malarials and steroids.

Immunosuppressive medications -- such as azathioprine and cyclosporine -- are also used to dampen an immune system gone haywire. However, such regimens, while effective, can provoke severe side effects.

"There hasn't been a drug approved [for lupus] by the FDA [U.S. Food and Drug Administration] for 40 years," Buyon said. "This is a time of major discovery, probably one of the most exciting times we'll ever see."

The current study, published in the Feb. 15 issue of Immunity, is a small one involving only 14 patients with lupus and an equal number of healthy controls.

Researchers did a genetic analysis of three different types of white blood cells and found that, in patients with more severe lupus, there was an increase in the activity of genes that normally would prevent the death of a cell, compar
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Bacterial toxin closes gate on immune response, Penn researchers discover
2. A functional immune system can be derived from embryonic stem cells, preliminary study finds
3. Some cases of autism may be traced to the immune system of mothers during pregnancy
4. Researchers discover new battleground for viruses and immune cells
5. MSU researchers make new discoveries on what does and doesnt affect immune system
6. U of M researchers discover a pathway to turn off immune system cells
7. Researchers uncover more about how poxviruses evade the immune system
8. A major step toward a more targeted treatment for auto-immune diseases?
9. Deficient regulators in the immune system responsible for type 1 diabetes
10. Queens immunologists find better way to boost the immune system
11. Immune Therapy May Help Some Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Overabundance of Immune Cells Might Trigger Lupus
Overabundance of Immune Cells Might Trigger Lupus
(Date:1/8/2009)..., Results of St. Jude study could shape new treat...., Jan. 8 Scientists at...trated a more effective treatment for bacterial pn...ntibiotics clindamycin and azithromycin, which kil...are more effective than a standard first-line trea...
(Date:1/8/2009)...eview says it lowered bad cholesterol more effecti...althDay News) -- After nearly a year of review, U....ted the continued use of the controversial cholest... Drug Administration said there was no significant...tients taking Vytorin and patients taking the drug...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -...pleased to announce that throughout the fourth qua..., Orthotics Center, Rocky Mountain Orthotic-Prosth...Services, Inc., First Coast Orthotics & Prosth.... These acquisitions add patient care centers to e...
(Date:1/8/2009)..., SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall...ounced that David Hung, M.D., president and chief,...l J.P. Morgan Healthcare,Conference on Wednesday,...tin,St. Francis Hotel in San Francisco. , ...d its clinical,development programs for Dimebon f...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
...management program cuts diabetes risk and is more ...s index (BMI) in overweight children. A family-b...chers at Yale School of Medicine was more successf...MI and insulin sensitivity than traditional clinic...
...rier cities like the Indian capital but also modif... warns a UN report released Wednesday. "Much of ...al areas from which they were first displaced," sa...lation 2007' report of the United Nations Populati...
...in Pakistan, evoking mixed reactions. <brThe...something extraordinary. Then the Lahore High Cou...comes as a pleasant surprise is the decision of th...e Court to release them on bail and hear their ap...
...ua, today welcomed Labors preventative health care... addressing Australias future health needs. Dr Ca...s ageing population and the increasing incidence o...including among younger people, will place great s...
Other Medicine News:Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:Same Sex Pair Get Relief in Pakistan 2Health News:Labor's Preventive Health Care Policy Looks to Address Future Needs 2
(Date:1/9/2009)...wire-FirstCall/ -- ProUroCare Medical Inc. (OTC Bu...of 3,050,000 units at $1.00 per unit, each unit co...emable warrant to purchase one share of common sto...mpany has granted the underwriter of the offering ...7,500 units to cover over-allotments, if any. The ...
(Date:1/9/2009)...re/ -- ESBATech AG, a leading developer of antibod...ation of the Phase I/IIa clinical development of i...eoarthritis (OA). This double-blind, randomized, p...signed to investigate the safety, tolerability and... intra-articular administration to patients with s...
(Date:1/8/2009)...wswire-FirstCall/ -- , - ThromboGenics, Lea...omacular Adhesion in the US and Europe , Th...nology company,focused on innovative treatments f...unces today that it has started the Phase III clin... treatment of back of the eye disease, the,final ...
(Date:1/8/2009)... second indication with clinical-stage, systemical...EMONT, Calif., Jan. 8 Quark Pharma...l company discovering and developing novel RNA int...ed that it has initiated patient dosing in its Pha... administered siRNA drug candidate QPI-1002 (previ...
Breaking Medicine Technology:ProUroCare Medical Inc. Announces Pricing of Equity Offering 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 2ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 3ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 4Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 2Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 3Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 4Tips from the Journals of the American Society for Microbiology 107 1Tips from the Journals of the American Society for Microbiology 107 2Tips from the Journals of the American Society for Microbiology 107 3Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 1Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 2St Jude influenza survey uncovers key differences between bird flu and human flu 106 1St Jude influenza survey uncovers key differences between bird flu and human flu 106 2St Jude influenza survey uncovers key differences between bird flu and human flu 106 3Stanford study highlights cost effective method of lowering heart disease risks 104 1Stanford study highlights cost effective method of lowering heart disease risks 104 2Stanford study highlights cost effective method of lowering heart disease risks 104 3
...ent with ISIS 301012 produced at least 45% additio...ded to,maximally-tolerated lipid-lowering therapie...tCall/ -- Isis,Pharmaceuticals, Inc. announced upd...al of ISIS 301012 in patients with homozygous,fami...of which were,presented in March at the of Cardiol...
...from Phase III pivotal trial demonstrate safety an...rol fumarate for,patients with moderate to severe ...- Dey, L.P. announced,that two clinical data prese...ence of the American Thoracic Society (ATS) on,Sun...o. The,presentations will detail Phase III clinica...
Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 2Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 3Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 4
Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches.
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches.
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches.
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches.
Medicine Products: